HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senators Push FDA For SPF Cap, Spray Sunscreen Review

This article was originally published in The Rose Sheet

Executive Summary

A group of Senators has sent a letter to FDA Commissioner Margaret Hamburg asking the agency to resolve sunscreen issues that remain in regulatory limbo. Led by Sen. Jack Reed, D-RI, the Senators urge FDA to establish a UV protection cap and thoroughly review spray sunscreens for safety.

You may also be interested in...



Sunscreen Bill Would Expedite TEA Decisions, Set Deadlines

The Sunscreen Innovation Act, introduced in both the House and the Senate, would streamline the process for FDA review of sunscreen TEAs and impose deadlines for agency action.

Obama Proposes Mostly Flat FY 2015 FDA Budget, Cosmetic User Fees

The federal fiscal 2015 budget proposal would provide $4.74 billion to FDA, representing a 2% increase overall versus fiscal 2014; however, the figure includes user fees that would have be enacted, including $19 million from the cosmetics industry.

Elizabeth Arden Goes Pro With TPF 50, Sets “New Standard” In Sunscreen

Elizabeth Arden ventures into pro skin-care with its Triple Protection Factor Broad Spectrum Sunscreen SPF 50+, which will be available in physicians’ offices, along with other Elizabeth Arden RX products, in April. Combining SPF with an Antioxidant Complex and DNA Enzyme Complex, TPF 50 is being touted as “the most effective topical skin protection on the market.”

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018572

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel